Differences in baseline characteristics and 1-year psychological factors between participants and non-participants in the randomized, controlled trial regarding patient-led follow-up after rectal cancer (FURCA)

Jakobsen, Ida Hovdenak; Juul, Therese; Thaysen, Henriette Vind; Johansen, Christoffer; Laurberg, Søren

doi:10.1080/0284186x.2019.1581948

Cited by 9 publications

(8 citation statements)

References 25 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eleven studies were conducted with Australian, 10 with Canadian, 5 with Dutch, and 3 with US samples, with the remaining studies conducted in various European and Asian countries. In these studies, data were generally presented as mean FCRI-total scores, and/or mean FCRI-SF scores, and/or as percentages using the FCRI-SF cut-offs of ≥13, 6,7,30-32,33-36 ≥16 17,33,37,38 or ≥22. 36,37 See Table 1 for further details. FCRI-total scores (score range 0-168) were reported in 25 studies, with mean scores ranging from 39.8 in a sample of prostate cancer survivors 11 to 113.5 in a sample of gynecological cancer survivors.…”

Section: Fcr Severity and Prevalence According To The Fcrimentioning

confidence: 99%

“…As seen in Table 1, in the nine studies 6,7,[30][31][32][33][34][35][36] using ≥13 on the FCRI-SF as a cutoff, more than half (53.9%) of participants scored above the cut-off. In the four studies 17,33,37,38 with data on the ≥16 cut-off, approximately 43.3% had scores indicating clinical levels of FCR. In the two samples 36,37 with data on the ≥22 cut-off, approximately one third (30%) had scores suggesting clinical levels of FCR.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)

Smith¹,

Costa²,

Galica³

et al. 2020

PRBM

View full text Add to dashboard Cite

Fear of cancer recurrence (FCR) is a pervasive concern for people living with cancer. The rapidly expanding FCR literature has been weakened somewhat by use of miscellaneous FCR measures of varying quality. The Fear of Cancer Recurrence Inventory (FCRI) has been widely used in observational and intervention studies and the FCRI severity subscale, also known as the FCRI-Short Form (FCRI-SF), is often used to identify potential cases of clinically significant FCR. Given the FCRI’s increasing use in research and clinical practice, we aimed to provide an overview, critique, and suggested improvements of the FCRI. Studies citing the original FCRI validation paper were identified and synthesised using narrative and meta-analytic methods. The 42-item FCRI has demonstrated a reasonably robust 7-factor structure across evaluations in multiple languages, although certain subscales (eg, Coping) demonstrate sub-optimal reliability. Confirmation of the cross-cultural equivalence of several FCRI translations is needed. Meta-analysis of FCRI-SF scores revealed a combined weighted mean score of 15.7/36, a little above the lowest proposed cut-off score (≥13) for clinical FCR. Depending on the FCRI-SF cut-off used, between 30.0% and 53.9% of the cancer population (ie, patients and survivors) appear to experience sub-clinical or clinical FCR. Higher FCRI scores were associated with younger age and female gender, pain/physical symptoms and psychological morbidity, consistent with the FCR literature generally. Issues regarding the application and interpretation of the FCRI remain. Whether the FCRI is well suited to assessing fear of progression as well as recurrence is unclear, the meaningfulness of the FCRI total score is debatable, and the use of the FCRI-SF to screen for clinical FCR is problematic, as items do not reflect established characteristics of clinical FCR. Refinement of the FCRI is needed for it to remain a key FCR assessment tool in future research and clinical practice.

show abstract

Section: Fcr Severity and Prevalence According To The Fcrimentioning

confidence: 99%

mentioning

confidence: 99%

Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)

Smith¹,

Costa²,

Galica³

et al. 2020

PRBM

View full text Add to dashboard Cite

show abstract

“…Patients included in clinical trials are not representative of the background population [49][50][51]. Population-based registries seldom include recurrence data, and if they do, they are unreliable, underestimating the risks [52,53].…”

Section: Representativitymentioning

confidence: 99%

Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?

Osterman

Hammarström

Imam

et al. 2020

Cancers

View full text Add to dashboard Cite

Adjuvant chemotherapy aims at eradicating tumour cells sometimes present after radical surgery for a colorectal cancer (CRC) and thereby diminish the recurrence rate and prolong time to recurrence (TTR). Remaining tumour cells will lead to recurrent disease that is usually fatal. Adjuvant therapy is administered based upon the estimated recurrence risk, which in turn defines the need for this treatment. This systematic overview aims at describing whether the need has decreased since trials showing that adjuvant chemotherapy provides benefits in colon cancer were performed decades ago. Thanks to other improvements than the administration of adjuvant chemotherapy, such as better staging, improved surgery, the use of radiotherapy and more careful pathology, recurrence risks have decreased. Methodological difficulties including intertrial comparisons decades apart and the present selective use of adjuvant therapy prevent an accurate estimate of the magnitude of the decreased need. Furthermore, most trials do not report recurrence rates or TTR, only disease-free and overall survival (DFS/OS). Fewer colon cancer patients, particularly in stage II but also in stage III, today display a sufficient need for adjuvant treatment considering the burden of treatment, especially when oxaliplatin is added. In rectal cancer, neo-adjuvant treatment will be increasingly used, diminishing the need for adjuvant treatment.

show abstract

“…A surgery alone group has, with one exception [19], not been present in trials performed for several decades. Patients included in clinical trials are selected and not representative of the background populations [20][21][22]. Population-based registries seldom include recurrence data and, if they do, they are unreliable, likely underestimating the risks [23,24].…”

Section: Introductionmentioning

confidence: 99%

Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer

et al. 2021

View full text Add to dashboard Cite

Background: The completeness and accuracy of the registration of synchronous metastases and recurrences in the Swedish Colorectal Cancer Registry has not been investigated. Knowing how accurate these parameters are in the registry is a prerequisite to adequately measure the current recurrence risk. Methods: All charts for patients diagnosed with stage I-III colorectal cancer (CRC) in two regions were reviewed. In one of the regions, all registrations of synchronous metastases were similarly investigated. After the database had been corrected, recurrence risk in colon cancer was calculated stratified by risk group as suggested by ESMO in 2020. Results: In patients operated upon more than five years ago (N ¼ 1235), there were 20 (1.6%) recurrences not reported. In more recent patients, more recurrences were unreported (4.0%). Few synchronous metastases were wrongly registered (3.6%) and, likewise, few synchronous metastases were not registered (about 1%). The five-year recurrence risk in stage II was 6% for low-risk, 11% for intermediate risk, and 23% for high-risk colon cancer patients. In stage III, it was 25% in low-and 45% in highrisk patients. Incorporation of risk factors in stage III modified the risks substantially even if this is not considered by ESMO. Adjuvant chemotherapy lowered the risk in stage III but not to any relevant extent in stage II. Conclusion: The registration of recurrences in the registry after 5 years is accurate to between 1 and 2% but less accurate earlier. A small number of unreported recurrences and falsely reported recurrences were discovered in the chart review. The recurrence risk in this validated and updated patient series matches what has been recently reported, except for the risk of recurrence in stage II low risk colon cancers which seem to be even a few percentage points lower (6 vs. 9%).

show abstract

Differences in baseline characteristics and 1-year psychological factors between participants and non-participants in the randomized, controlled trial regarding patient-led follow-up after rectal cancer (FURCA)

Abstract: behalf of the FURCA project group (2019) Differences in baseline characteristics and 1-year psychological factors between participants and non-participants in the randomized, controlled trial regarding patient-led follow-up after rectal cancer (FURCA), Acta

Cited by 9 publications

References 25 publications

Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)

Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)

Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?

Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer

Contact Info

Product

Resources

About